These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 30341021

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Incidence of anogenital warts after the introduction of the quadrivalent HPV vaccine program in Manitoba, Canada.
    Righolt CH, Willows K, Kliewer EV, Mahmud SM.
    PLoS One; 2022; 17(4):e0267646. PubMed ID: 35472093
    [Abstract] [Full Text] [Related]

  • 3. Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals.
    Nygård S, Nygård M, Orumaa M, Hansen BT.
    Vaccine; 2023 Aug 23; 41(37):5469-5476. PubMed ID: 37516572
    [Abstract] [Full Text] [Related]

  • 4. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy.
    Carozzi F, Puliti D, Ocello C, Anastasio PS, Moliterni EA, Perinetti E, Serradell L, Burroni E, Confortini M, Mantellini P, Zappa M, Dominiak-Felden G.
    BMC Infect Dis; 2018 Jan 15; 18(1):38. PubMed ID: 29334901
    [Abstract] [Full Text] [Related]

  • 5. The early impact of human papillomavirus vaccination on anogenital warts in Québec, Canada.
    Steben M, Ouhoummane N, Rodier C, Sinyavskaya L, Brassard P.
    J Med Virol; 2018 Mar 15; 90(3):592-598. PubMed ID: 28980715
    [Abstract] [Full Text] [Related]

  • 6. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.
    Drolet M, Bénard É, Pérez N, Brisson M, HPV Vaccination Impact Study Group.
    Lancet; 2019 Aug 10; 394(10197):497-509. PubMed ID: 31255301
    [Abstract] [Full Text] [Related]

  • 7. Human Papillomavirus Vaccination and Cervical Cytology Outcomes Among Urban Low-Income Minority Females.
    Hofstetter AM, Ompad DC, Stockwell MS, Rosenthal SL, Soren K.
    JAMA Pediatr; 2016 May 01; 170(5):445-52. PubMed ID: 26974250
    [Abstract] [Full Text] [Related]

  • 8. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER, Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices (ACIP).
    MMWR Recomm Rep; 2007 Mar 23; 56(RR-2):1-24. PubMed ID: 17380109
    [Abstract] [Full Text] [Related]

  • 9. Effectiveness of school-based and high-risk human papillomavirus vaccination programs against cervical dysplasia in Manitoba, Canada.
    Righolt CH, Bozat-Emre S, Mahmud SM.
    Int J Cancer; 2019 Aug 01; 145(3):671-677. PubMed ID: 30653261
    [Abstract] [Full Text] [Related]

  • 10. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study.
    Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM.
    BMC Med; 2013 Oct 22; 11():227. PubMed ID: 24148310
    [Abstract] [Full Text] [Related]

  • 11. Effectiveness of the quadrivalent human papillomavirus vaccine against cervical dysplasia in Manitoba, Canada.
    Mahmud SM, Kliewer EV, Lambert P, Bozat-Emre S, Demers AA.
    J Clin Oncol; 2014 Feb 10; 32(5):438-43. PubMed ID: 24395857
    [Abstract] [Full Text] [Related]

  • 12. The early benefits of human papillomavirus vaccination on cervical dysplasia and anogenital warts.
    Smith LM, Strumpf EC, Kaufman JS, Lofters A, Schwandt M, Lévesque LE.
    Pediatrics; 2015 May 10; 135(5):e1131-40. PubMed ID: 25917991
    [Abstract] [Full Text] [Related]

  • 13. Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada.
    Goggin P, Sauvageau C, Gilca V, Defay F, Lambert G, Mathieu-C S, Guenoun J, Comète E, Coutlée F.
    Hum Vaccin Immunother; 2018 Jan 02; 14(1):118-123. PubMed ID: 29049007
    [Abstract] [Full Text] [Related]

  • 14. Early impact of Ontario's human papillomavirus (HPV) vaccination program on anogenital warts (AGWs): A population-based assessment.
    Guerra FM, Rosella LC, Dunn S, Wilson SE, Chen C, Deeks SL.
    Vaccine; 2016 Sep 07; 34(39):4678-4683. PubMed ID: 27527815
    [Abstract] [Full Text] [Related]

  • 15. Early Evidence of the Effectiveness of the Human Papillomavirus Vaccination Program Against Anogenital Warts in Manitoba, Canada: A Registry Cohort Study.
    Willows K, Bozat-Emre S, Righolt CH, Kliewer EV, Mahmud SM.
    Sex Transm Dis; 2018 Apr 07; 45(4):254-259. PubMed ID: 29465699
    [Abstract] [Full Text] [Related]

  • 16. The impact of HPV multi-cohort vaccination: Real-world evidence of faster control of HPV-related morbidity.
    Orumaa M, Kjaer SK, Dehlendorff C, Munk C, Olsen AO, Hansen BT, Campbell S, Nygård M.
    Vaccine; 2020 Feb 05; 38(6):1345-1351. PubMed ID: 31917039
    [Abstract] [Full Text] [Related]

  • 17. The Efficacy of the Quadrivalent Human Papillomavirus Vaccine in Girls and Women Living With Human Immunodeficiency Virus.
    McClymont E, Lee M, Raboud J, Coutlée F, Walmsley S, Lipsky N, Loutfy M, Trottier S, Smaill F, Klein MB, Harris M, Cohen J, Yudin MH, Wobeser W, Money D, CTN 236 HPV in HIV Study Team.
    Clin Infect Dis; 2019 Feb 15; 68(5):788-794. PubMed ID: 29985988
    [Abstract] [Full Text] [Related]

  • 18. Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs.
    Markowitz LE, Drolet M, Perez N, Jit M, Brisson M.
    Vaccine; 2018 Aug 06; 36(32 Pt A):4806-4815. PubMed ID: 29802000
    [Abstract] [Full Text] [Related]

  • 19. Evaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort Study.
    Dominiak-Felden G, Gobbo C, Simondon F.
    PLoS One; 2015 Aug 06; 10(7):e0132404. PubMed ID: 26147096
    [Abstract] [Full Text] [Related]

  • 20. Canadian school-based HPV vaccine programs and policy considerations.
    Shapiro GK, Guichon J, Kelaher M.
    Vaccine; 2017 Oct 09; 35(42):5700-5707. PubMed ID: 28893472
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.